Tag: NCT03568461

Home / NCT03568461

Categories

Tisagenlecleucel is approved by FDA for relapsed or refractory follicular lymphoma

June 2022: After two or more lines of systemic therapy, the FDA awarded tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) expedited approval for adult patients with relapsed or refract...
nct03568461

Scan the code